Shukra Pharmaceuticals L
NSE: SHUKRAPHAR · Pharmaceuticals · sector
₹67.46NSE close 2026-10-26
Key numbers
Market cap₹2,954 cr
Price₹67.46
52w high / low₹75 / ₹40
P/E78.4xSector median 27.9x
P/B32.9xSector median 2.9x
Book value₹2.0
Dividend yield0.02%Sector median 0.48%
ROE44.1%Sector median 11.7%
ROCE49.1%Sector median 12.3%
OPM61.8%Sector median 14.0%
Debt / equity0.06xSector median 0.16x
EV/EBITDA63.8xSector median 18.6x
Interest cover37.1x
Current ratio3.63x
Sales growth 3y-1.2%Sector median +9.6%
Profit growth 3y+71.0%Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹6 cr vs borrowings ₹5 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 37.1x in the last 12 months.
- Net loss in 1 of the last 6 quarters.
- Other income was 12% of net profit in the last 12 months.
- No dividend in the last 5 financial years.
- Price ₹67.46 on 2026-10-26: -10.5% from the 52-week high, +68.4% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹68.88 · low ₹12.69
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 13 | 5 | 6 | 39 | 6 | 24 |
| EBITDA | 7 | 1 | -0 | 27 | 0 | 19 |
| OPM % | 55.2% | 24.5% | -7.1% | 69.4% | 6.3% | 81.4% |
| Other income | 1 | 1 | 2 | 1 | 1 | 1 |
| Net profit | 5 | 1 | 2 | 20 | -2 | 13 |
| EPS (₹) | 0.12 | 0.02 | 0.05 | 0.47 | 0.04 | 0.30 |
| Revenue YoY | -52.4% | +336.4% | ||||
| Profit YoY | -137.5% | +1,158.3% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 20 | 59 | 75 | 33 | 57 | 75 |
| EBITDA | 3 | 5 | 19 | 13 | 29 | 46 |
| Net profit | 1 | 4 | 19 | 10 | 22 | 34 |
| EPS (₹) | 4.79 | 26.21 | 16.93 | 0.22 | 0.50 | 0.86 |
| Revenue growth | +187.1% | +26.8% | -56.3% | +74.1% | – | |
| Profit growth | +488.0% | +320.4% | -48.3% | +130.3% | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -1.2% | – | – |
| Net profit | +71.0% | – | – |
| EPS | -73.3% | – | – |
| Share price | – | – (2y) | – |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 63 | 90 |
| Borrowings | 4 | 5 |
| Cash & equivalents | 12 | 6 |
| Total assets | 87 | 117 |
| Fixed assets | 19 | 22 |
| Capital work in progress | 2 | 12 |
| Investments | 0 | 0 |
| Receivables | 9 | 23 |
| Inventory | 10 | 14 |
| Payables | 9 | 10 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 8 | 4 |
| Cash from investing | -1 | -14 |
| Cash from financing | -5 | 4 |
| Capex | 3 | 0 |
| Free cash flow | 5 | 4 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 15.2% | 24.6% |
| ROCE % | 20.8% | 31.5% |
| Debtor days | 98 | 148 |
| Inventory days | 448 | 320 |
| Payable days | 415 | 232 |
| Cash conversion cycle (days) | 131 | 236 |
| Working capital days | 539 | 391 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 51.15% |
| FIIs | 0.44% |
| DIIs | 0.22% |
| of which Mutual funds | 0.00% |
| Public (non-institutions) | 48.20% |
| Quarter | Sep 2026 |
|---|---|
| Promoters % | 51.15% |
| Promoter group | % |
|---|---|
| Anar Project Private Limited | 18.71% |
| Parshva Texchem India Private Ltd. | 17.38% |
| Navkar Surgical Gujarat | 11.74% |
| Dakshesh Rameshchandra Shah | 1.11% |
| Anar Jayeshbhai Patel | 0.99% |
| Sujay Jyotindra Mehta | 0.71% |
| Payal Sujay Mehta | 0.52% |
| Public holders above 1% | % |
|---|---|
| Renuka Yogesh Parikh | 19.11% |
| Yogesh Biharilal Parikh | 17.56% |
35,007 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| SHUKRAPHAR | ₹2,954 cr | 78.4x | 32.9x | 44.1% | 49.1% | 61.8% | -1.2% | 0.02% |
Business segments (2026-06-30)
| Segment | Revenue | Share | EBIT | Margin |
|---|---|---|---|---|
| pharmaceutical segment | ₹24 cr | 100.0% | ₹19 cr | 77.3% |
| Medtech segment | ₹0 cr | – | ₹0 cr | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-09-21 | Dividend | Dividend - Re 0.01 Per Share |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | SHUKRAPHAR |
| BSE code | 524632 |
| ISIN | INE551C01044 |
| Face value | ₹1.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-22 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years, NSE shareholding & pledge data; price = NSE close 2026-10-26.